Presentation Scheduled for Wednesday, May 7th at 9:30am EDT
NEW YORK, May 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, is scheduled to present at the Deutsche Bank 33rd Annual Health Care Conference in Boston, Massachusetts.
Mr. Weiss' presentation, which will take place on Wednesday, May 7th at 9:30am EDT, will be webcast live and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals is focused on the acquisition, development and
commercialization of medically important, novel pharmaceutical products for
the treatment of life-threatening diseases, including renal disease and
cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral,
iron-based compound that has the capacity to bind to phosphate and form
non-absorbable complexes. Zerenex is currently in Phase 2 clinical
development for the treatment of hyperphosphatemia (elevated phosphate
levels) in patients with end-stage renal disease, or ESRD. The Company is
also developing KRX-0401 (perifosine), a novel, potentially first-in-class,
oral anti-cancer agent that modulates Akt, a protein in the body associated
with tumor survival and growth. KRX-0401 also modulates a number of other
key signal transduction pathways, including the JNK and MAPK pathways,
which are pathways associated with programmed cell death, cell growth, cell
differentiation and cell surviva
|SOURCE Keryx Biopharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved